CO2021014155A2 - Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 - Google Patents

Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2

Info

Publication number
CO2021014155A2
CO2021014155A2 CONC2021/0014155A CO2021014155A CO2021014155A2 CO 2021014155 A2 CO2021014155 A2 CO 2021014155A2 CO 2021014155 A CO2021014155 A CO 2021014155A CO 2021014155 A2 CO2021014155 A2 CO 2021014155A2
Authority
CO
Colombia
Prior art keywords
mrgx2
thiadiazine
benzo
inhibitors
amino
Prior art date
Application number
CONC2021/0014155A
Other languages
English (en)
Inventor
Simone Bigi
Allison L Chambers
Tony Gibson
Jason Pickens
Steve Swann
Angie Vassar
Feng Zhou
Mitsunori Kono
Masaki Seto
Zenyu Shiokawa
Original Assignee
Solent Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solent Therapeutics Llc filed Critical Solent Therapeutics Llc
Publication of CO2021014155A2 publication Critical patent/CO2021014155A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/32—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la Fórmula 1, , tautómeros de los mismos, y sales farmacéuticamente aceptables de los compuestos o tautómeros, en donde L, R1, R2, R3, R4 y R5 son definidos en la especificación. Esta descripción también se refiere a materiales y métodos para preparar compuestos de la Fórmula 1, a las composiciones farmacéuticas que las contienen, y a su uso para tratar enfermedades, trastornos o afecciones asociadas con MRGX2.
CONC2021/0014155A 2019-04-29 2021-10-22 Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 CO2021014155A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962840344P 2019-04-29 2019-04-29
PCT/US2020/030305 WO2020223255A1 (en) 2019-04-29 2020-04-28 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2

Publications (1)

Publication Number Publication Date
CO2021014155A2 true CO2021014155A2 (es) 2021-10-29

Family

ID=70779887

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014155A CO2021014155A2 (es) 2019-04-29 2021-10-22 Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2

Country Status (22)

Country Link
US (1) US20220119361A1 (es)
EP (1) EP3962901A1 (es)
JP (1) JP2022535672A (es)
KR (1) KR20220012244A (es)
CN (1) CN114072393A (es)
AR (1) AR119728A1 (es)
AU (1) AU2020266529A1 (es)
BR (1) BR112021021508A2 (es)
CA (1) CA3137584A1 (es)
CL (1) CL2021002805A1 (es)
CO (1) CO2021014155A2 (es)
CR (1) CR20210544A (es)
DO (1) DOP2021000223A (es)
EC (1) ECSP21080966A (es)
IL (1) IL287521A (es)
JO (1) JOP20210275A1 (es)
MA (1) MA55804A (es)
MX (1) MX2021013135A (es)
PE (1) PE20220425A1 (es)
SG (1) SG11202111717XA (es)
TW (1) TW202106669A (es)
WO (1) WO2020223255A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR122450A1 (es) * 2020-05-08 2022-09-14 Lilly Co Eli Compuestos de (trifluorometil)pirimidin-2-amina
WO2022152852A1 (en) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonists of mrgx2
WO2022152853A1 (en) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonists of mrgx2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20060217370A1 (en) * 2005-02-18 2006-09-28 Ethan Burstein Compounds useful for the treatment and prevention of pain and screening methods therefor
US20080249081A1 (en) * 2006-10-24 2008-10-09 Roger Olsson Compounds for the treatment of pain and screening methods therefor

Also Published As

Publication number Publication date
US20220119361A1 (en) 2022-04-21
PE20220425A1 (es) 2022-03-29
EP3962901A1 (en) 2022-03-09
DOP2021000223A (es) 2022-01-16
AR119728A1 (es) 2022-01-05
KR20220012244A (ko) 2022-02-03
SG11202111717XA (en) 2021-11-29
AU2020266529A1 (en) 2021-12-16
JP2022535672A (ja) 2022-08-10
CN114072393A (zh) 2022-02-18
ECSP21080966A (es) 2022-01-31
CR20210544A (es) 2022-03-30
MA55804A (fr) 2022-04-06
BR112021021508A2 (pt) 2022-03-22
CA3137584A1 (en) 2020-11-05
JOP20210275A1 (ar) 2023-01-30
CL2021002805A1 (es) 2022-07-22
TW202106669A (zh) 2021-02-16
MX2021013135A (es) 2021-11-25
IL287521A (en) 2021-12-01
WO2020223255A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
CO2021014155A2 (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
CO2022000480A2 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
UY30327A1 (es) Nuevos compuestos ii
BR112018007772A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
UY31471A1 (es) Derivados bis-(sulfonilamino) en terapia 066
UY30328A1 (es) Derivados de 2-piridona, procesos de preparacion, composiciones conteniéndolos y aplicaciones.
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
PE20050089A1 (es) Derivados de azo [1,2-c] quinazolina condensados
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
PA8622801A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
DOP2022000057A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
CO2022004698A2 (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
ECSP18056196A (es) Derivados de indano
CL2020000439A1 (es) Sales de un compuesto y sus formas cristalinas.
CO2017007189A2 (es) Derivados de fumagilol
ECSP22091230A (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
AR049638A1 (es) Derivados de benzileter, su elaboracion, su uso para preparar agentes farmaceuticos y composicion farmaceutica